Health Canada Summary Basis of Decision 2019-01-25. Xermelo, telotristat ethyl (as telotristat etiprate), 250 mg, tablet, Ipsen Biopharmaceuticals Canada Inc.. Submission Control Number 208730.
Related Posts
Post-Authorization Activity Table (PAAT) for Ofev
February 11, 2019
Regulatory Decision Summary for ORILISSA
February 11, 2019